



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>4</sup> :</b> A61K 49/00, 39/00, C07K 15/14 C12N 1/00	<b>A1</b>	<b>(11) International Publication Number:</b> WO 90/03801 <b>(43) International Publication Date:</b> 19 April 1990 (19.04.90)
<b>(21) International Application Number:</b> PCT/US89/04513 <b>(22) International Filing Date:</b> 11 October 1989 (11.10.89)  <b>(30) Priority data:</b> 255,513 11 October 1988 (11.10.88) US Not furnished 4 October 1989 (04.10.89) US  <b>(71) Applicant:</b> UNIVERSITY OF SOUTHERN CALIFORNIA [US/US]; 3716 Hope Street, 200, Los Angeles, CA 90007-4344 (US).  <b>(72) Inventors:</b> EPSTEIN, Alan, L. ; 5128 Hillard Avenue, La Canada, CA 91011 (US). GLOVSKY, Michael, M. ; 750 Malcolm Avenue, Los Angeles, CA 90024 (US).  <b>(74) Agents:</b> SIMPSON, Andrew, H. et al.; Knobbe, Martens, Olson and Bear, 620 Newport Center Drive, 16th Floor, Newport Beach, CA 92660 (US).		<b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> VASOPERMEABILITY-ENHANCING CONJUGATES  <b>(57) Abstract</b>  Conjugates having a clinically useful delivery vehicle linked to a biologically active species which acts to increase vascular permeability and expand blood volume at or in proximity to the tumor site are disclosed. The vehicle-linked species may be, for example, a vasoactive agent, a substance that recruits or amplifies a vasoactive species, a toxin, a drug, an isotope, or a pharmaceutical compound. Suitable biological species comprises peptides, lipids, carbohydrates, or their derivatives. Chemical or recombinant DNA methods suitable for linking the species to the vehicles are indicated. A therapy is disclosed which comprises administering the vasoactive conjugate and delivering a diagnostic agent or a therapeutic agent at an optimal time thereafter, when tumor vasculature is maximally expanded.		